Human brains differ remarkably in size, shape and cellular composition from the animal models used in pre-clinical research. Differences at the molecular and cellular levels set our brains even further apart from these models. In particular, human cortical neurons have in comparison to rodent models larger dendritic trees, distinct electrophysical properties, ten times the capacity to transfer information, as well as different types of protein isoforms and 30% additional proteins present in their synapses. Not surprisingly, the translation of findings derived from animal models to the clinic has been proven to be very limited (especially for neurological indications whereby less than 10% of the pre-clinical drug candidates are entering the clinic). Therefore, human in vitro models will be invaluable for drug development in order to reduce costs, improve discovery screen specificity, and potentially save lives. Human iPSC-derived neurons are an attractive in vitro model for high content drug screening platforms. However, directed differentiation protocols that use extrinsic factors are often complex, lengthy, expensive, inconsistent, and generate mixed cell populations. In contrast, transcription factors which operate in a cell intrinsic manner have the extraordinary ability to efficiently reprogram cells toward specific cell types. This methods collection aims to collate advanced approaches that utilize cellular reprogramming in order  to model neurological diseases, and will include methods describing; (1) the identification and screening for transcription factors critical for cellular reprogramming; (2) viral and non-viral based delivery systems to reprogram cells; and (3) the use of reprogrammed cells in neurological disease modelling.